Obesity
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, weak associations between HSD11B1 genotype, increased 11beta-HSD1 activity, and W:H ratio suggest that polymorphic variability at the HSD11B1 locus may influence susceptibility to central obesity through enhanced 11beta-HSD1 activity (E to F conversion) in visceral adipose tissue.
|
12414862 |
2002 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
The activity of the glucocorticoid activating enzyme, 11β-hydroxysteroid dehydrogenase type-1 (11βHSD1) is altered in diseases such as obesity, inflammation and psychiatric disorders.
|
31677354 |
2019 |
Obesity
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The mechanism of this up-regulation remains uncertain; polymorphisms in the HSD11B1 gene have been associated with metabolic complications of obesity, including hypertension and type 2 diabetes, but not with obesity per se.
|
17343766 |
2007 |
Obesity
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A novel SNP, rs3753519, was strongly associated with obesity and this SNP was the only statistically significant HSD11B1 gene SNP remaining after a Bonferroni correction (odds ratio=1.97 for allelic effect, 95% confidence interval 1.23-3.16; P=0.004 and Bonferroni corrected P=0.046).
|
22310475 |
2012 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Polymorphisms in 11-β hydroxysteroid dehydrogenase type 1 (11β-HSD1, encoded by HSD11B1) have been reported to be associated with obesity-related cardiovascular risk factors, such as type II diabetes and hypertension.
|
21402901 |
2011 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, 11β-HSD1 is a promising target for the treatment and prevention of type 2 diabetes mellitus with obesity.
|
29078846 |
2017 |
Obesity
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that 11β-HSD1 activity is dysregulated in obesity and alters following bariatric surgery induced weight loss in different tissues.
|
25603461 |
2015 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Animal studies indicate a role for 11beta-hydroxysteroid dehydrogenase type 1 (HSD11B1) in the development of obesity.
|
20381186 |
2010 |
Obesity
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of liver reductases in obesity could be an adaptive response to an increase in cortisol production by the liver and visceral 11β-HSD1 to avoid systemic hypercortisolism.
|
21704348 |
2011 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
The current obesity epidemic, however, is not characterized by increased plasma cortisol concentrations, but instead comes along with chronic low-grade inflammation in adipose tissue and concomitant increased levels of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1, gene HSD11B1), a parameter known to cause obesity in a mouse model.
|
20045052 |
2010 |
Obesity
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in HSD11B1, the gene encoding 11β-hydroxysteroid dehydrogenase type 1 enzyme, have been associated with obesity, metabolic syndrome, and type 2 diabetes.
|
21117953 |
2011 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Homozygosity for 11-βHSD1 4478G/G was absent with no association with parameters of obesity and insulin resistance.
|
24078163 |
2013 |
Obesity
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moreover, 11β-HSD1 was expressed in crown ATMs in obese AT.
|
27698011 |
2016 |
Obesity
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The steadily increasing epidemic of obesity continues at alarming rates, is an important public health problem, and expression changes of S100A16 and 11 β-hydroxysteroid dehydrogenase type 1(11β-HSD1) is attributable to the adipocyte differentiation.
|
31399502 |
2019 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Studies have implicated 11β-HSD1 in metabolic diseases including type 2 diabetes and obesity, as well as stress-related disorders and neurodegenerative diseases, such as depression and Alzheimer's disease (AD).
|
30689943 |
2019 |
Obesity
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our objective was to investigate a functional polymorphism in HSD11B1 (T-->G in the third intron rs12086634, which associates with lower 11beta-HSD1 activity) in PCOS with and without obesity.
|
16551740 |
2006 |
Obesity
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To investigate the relationship between 11β-hydroxysteroid dehydrogenase (HSD11B) gene type 1 and 2 and obesity in Chinese children.
|
24729284 |
2014 |
Obesity
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that obesity and elevated intracranial pressure may be linked through increased 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity.
|
20826586 |
2010 |
Obesity
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We suggest that the disruption of Ifi202b in B6 is responsible for the effects of the obesity QTL Nob3, and that Ifi202b modulates fat accumulation through expression of adipogenic genes such as 11β-Hsd1.
|
22692684 |
2012 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study suggests that there are sex differences in 11β-HSD1 regulation and in its associations with markers of obesity and IR.
|
23701286 |
2013 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, the link between the role of 11β-HSD1 in the hypothalamus and obesity has yet to be determined.
|
29418022 |
2018 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
This mini-review will focus on 11β-HSD1 in skeletal muscle and its postulated link to obesity and insulin-resistance.
|
28765040 |
2017 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
The impact of adipose tissue cortisol reactivation by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) on markers of obesity and IR was assessed in PCOS patients.
|
21147223 |
2011 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
Regeneration of cortisol by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) within liver and adipose tissue may be of pathophysiological importance in obesity and the metabolic syndrome. single nucleotide polymorphisms (SNPs) in HSD11B1, the gene encoding 11β-HSD1, have been associated with type 2 diabetes and hypertension in population-based cohort studies, and with hyperandrogenism in patients with the polycystic ovary syndrome (PCOS).
|
21622477 |
2011 |
Obesity
|
0.600 |
Biomarker
|
disease |
BEFREE |
11beta-hydroxysteroid dehydrogenase type 1 (HSD11B1), which converts inactive cortisone to active cortisol, has become an emerging therapeutic target for type 2 diabetes mellitus and obesity.
|
19571556 |
2009 |